-
Mantle Cell Lymphoma
5000612
global
1
0.5
0.5
Commentary
0
1
Hematology-Oncology2023-03-29 20:00:00
Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
0
global
1
0.25
9
0.25
2
0.25
3
0.25
8
0.25
0.25
Clinical Case
0
1
Hematology-Oncology2023-03-29 20:00:00
How much attention do you pay to the role of caregivers?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Social Determinants of Health
6010999
global
1
0.25
9
0.25
2
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-03-28 20:00:00
How confident are you at recognizing and addressing inequities in the care of patients with hematologic malignancies?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Breast Cancer
840
global
1
0.75
9
0.75
2
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-03-28 20:00:00
What do the guidelines say about treating patients with early breast cancer at high risk for recurrence?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Myelofibrosis
5003320
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-03-27 20:00:00
Did you know new treatments in development are being developed for myelofibrosis with the goal of changing the disease course?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Ovarian Cancer
839
global
1
1.0
9
1.0
1.0
Clinical Case
0
1
Hematology-Oncology2023-03-26 20:00:00
Integrating maintenance therapy into treatment for patients with ovarian cancer
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Mantle Cell Lymphoma
5000612
global
1
0.5
0.5
Commentary
0
1
Hematology-Oncology2023-03-29 20:00:00
Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
0
global
1
0.25
9
0.25
2
0.25
3
0.25
8
0.25
0.25
Clinical Case
0
1
Hematology-Oncology2023-03-29 20:00:00
How much attention do you pay to the role of caregivers?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Social Determinants of Health
6010999
global
1
0.25
9
0.25
2
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-03-28 20:00:00
How confident are you at recognizing and addressing inequities in the care of patients with hematologic malignancies?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Breast Cancer
840
global
1
0.75
9
0.75
2
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-03-28 20:00:00
What do the guidelines say about treating patients with early breast cancer at high risk for recurrence?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Myelofibrosis
5003320
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-03-27 20:00:00
Did you know new treatments in development are being developed for myelofibrosis with the goal of changing the disease course?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Ovarian Cancer
839
global
1
1.0
9
1.0
1.0
Clinical Case
0
1
Hematology-Oncology2023-03-26 20:00:00
Integrating maintenance therapy into treatment for patients with ovarian cancer
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Acute Leukemia
5005273
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-03-26 20:00:00
Hear updates from the winter meetings on novel approaches for getting older patients with acute myeloid leukemia (AML) to transplant.
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Breast Cancer
840
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-26 20:00:00
Which of the guidelines for use of CDK 4/6 inhibitors do you use to guide treatment for patients with HR-positive/HER2-negative early breast cancer?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Multiple Myeloma
1166
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-03-26 20:00:00
What is the optimal approach to treatment for first and second relapse? Dr Lonial provides practical guidance.
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Lung Cancer
5000186
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2023-03-26 20:00:00
Do you know how to manage patients with solid tumors and NTRK fusions?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Non-Hodgkin Lymphoma (NHL)
1544
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Hematology-Oncology2023-03-26 20:00:00
Looking for updates on the latest in bispecific antibodies in B-cell non-Hodgkin lymphoma (NHL)? Join for expert analysis to incorporate these novel agents into practice.
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Small Cell Lung Cancer
275
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Neurology & Neurosurgery2023-03-23 20:00:00
When an autoimmune neuromuscular disease signals the presence of small cell carcinoma.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Advanced and Metastatic Breast Cancer
846
global
1
0.25
9
0.25
0.25
Commentary
0
1
Hematology-Oncology2023-03-22 20:00:00
Aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). How do they work and when should they be added to the treatment of metastatic hormone receptor (HR)-positive breast cancer?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Breast Cancer
840
global
1
1.0
9
1.0
1.0
Clinical Case
0
1
Hematology-Oncology2023-03-20 20:00:00
Do you know the best approaches for identifying and managing high-risk, hormone receptor positive early breast cancer?
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
0
global
1
1.0
9
1.0
1.0
Clinical Case
0
1
Hematology-Oncology2023-03-20 20:00:00
Did you know that pyruvate kinase deficiency (PKD) is diagnosed using a combination of PK enzyme activity and PKLR molecular profiling?
1.0ABIM MOC
1.0CME/CE
60MIN
Save
-
Chronic Lymphocytic Leukemia
1551
global
1
0.75
9
0.75
0.75
Commentary
0
1
Hematology-Oncology2023-03-20 20:00:00
Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Chronic Myelogenous Leukemia
1552
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-19 20:00:00
How do you choose a tyrosine kinase inhibitor (TKI) for your patients with chronic myeloid leukemia (CML)? Join to hear an expert discussion on considerations and clinical data.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Colorectal Cancer
3032296
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-19 20:00:00
Did you know that patients with left-sided colorectal cancer (CRC) tend to have greater overexpression of human epidermal growth factor receptor-2 (HER2) than those with right-sided disease?
0.5ABIM MOC
0.5CME/CE
30MIN
Save